Urogen Pharma Stock Price History
| URGN Stock | USD 11.91 0.36 3.12% |
Below is the normalized historical share price chart for UroGen Pharma extending back to May 04, 2017. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of UroGen Pharma stands at 11.91, as last reported on the 24th of November, with the highest price reaching 12.04 and the lowest price hitting 11.50 during the day.
If you're considering investing in UroGen Stock, it is important to understand the factors that can impact its price. UroGen Pharma owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0827, which indicates the firm had a -0.0827% return per unit of risk over the last 3 months. UroGen Pharma exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate UroGen Pharma's Coefficient Of Variation of (1,144), variance of 8.27, and Risk Adjusted Performance of (0.06) to confirm the risk estimate we provide.
At this time, UroGen Pharma's Other Stockholder Equity is very stable compared to the past year. As of the 24th of November 2024, Common Stock is likely to grow to about 93.5 K, though Total Stockholder Equity is likely to grow to (62 M). . As of the 24th of November 2024, Price Earnings To Growth Ratio is likely to grow to 0.17, while Price To Sales Ratio is likely to drop 4.97. UroGen Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 4th of May 2017 | 200 Day MA 14.5378 | 50 Day MA 12.3958 | Beta 1.126 |
UroGen |
Sharpe Ratio = -0.0827
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | URGN |
Estimated Market Risk
| 2.89 actual daily | 25 75% of assets are more volatile |
Expected Return
| -0.24 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average UroGen Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of UroGen Pharma by adding UroGen Pharma to a well-diversified portfolio.
Price Book 19.698 | Enterprise Value Ebitda (2.63) | Price Sales 5.6242 | Shares Float 24.5 M | Wall Street Target Price 39.9286 |
UroGen Pharma Stock Price History Chart
There are several ways to analyze UroGen Stock price data. The simplest method is using a basic UroGen candlestick price chart, which shows UroGen Pharma price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
| Highest Price | September 4, 2024 | 13.97 |
| Lowest Price | November 18, 2024 | 11.04 |
UroGen Pharma November 24, 2024 Stock Price Synopsis
Various analyses of UroGen Pharma's daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell UroGen Stock. It can be used to describe the percentage change in the price of UroGen Pharma from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of UroGen Stock.| UroGen Pharma Price Rate Of Daily Change | 1.03 | |
| UroGen Pharma Price Daily Balance Of Power | 0.67 | |
| UroGen Pharma Price Action Indicator | 0.32 |
UroGen Pharma November 24, 2024 Stock Price Analysis
UroGen Stock Price History Data
The price series of UroGen Pharma for the period between Mon, Aug 26, 2024 and Sun, Nov 24, 2024 has a statistical range of 3.41 with a coefficient of variation of 6.33. The daily prices for the period are distributed with arithmetic mean of 12.73. The median price for the last 90 days is 12.7.| Open | High | Low | Close | Volume | ||
11/24/2024 | 11.60 | 12.04 | 11.50 | 11.91 | ||
| 11/22/2024 | 11.60 | 12.04 | 11.50 | 11.91 | 390,577 | |
| 11/21/2024 | 11.53 | 11.82 | 11.31 | 11.55 | 549,662 | |
| 11/20/2024 | 11.13 | 11.48 | 10.86 | 11.45 | 431,834 | |
| 11/19/2024 | 10.97 | 11.23 | 10.86 | 11.16 | 326,646 | |
| 11/18/2024 | 11.21 | 11.60 | 10.62 | 11.04 | 797,187 | |
| 11/15/2024 | 11.95 | 11.95 | 11.16 | 11.19 | 546,105 | |
| 11/14/2024 | 12.09 | 12.34 | 11.76 | 11.86 | 363,991 | |
| 11/13/2024 | 12.51 | 12.78 | 12.11 | 12.16 | 428,014 | |
| 11/12/2024 | 12.65 | 12.67 | 12.22 | 12.35 | 455,703 | |
| 11/11/2024 | 12.28 | 12.81 | 12.08 | 12.79 | 433,940 | |
| 11/08/2024 | 12.05 | 12.30 | 11.93 | 12.12 | 212,843 | |
| 11/07/2024 | 12.24 | 12.53 | 12.01 | 12.10 | 304,013 | |
| 11/06/2024 | 13.25 | 13.37 | 11.76 | 12.24 | 687,318 | |
| 11/05/2024 | 11.93 | 12.30 | 11.66 | 12.21 | 534,468 | |
| 11/04/2024 | 12.15 | 12.33 | 11.84 | 11.93 | 345,357 | |
| 11/01/2024 | 12.33 | 12.66 | 12.07 | 12.20 | 603,192 | |
| 10/31/2024 | 13.02 | 13.13 | 12.24 | 12.26 | 395,057 | |
| 10/30/2024 | 12.22 | 13.33 | 12.16 | 13.02 | 943,655 | |
| 10/29/2024 | 12.10 | 12.45 | 12.03 | 12.25 | 423,401 | |
| 10/28/2024 | 12.26 | 12.54 | 12.15 | 12.15 | 246,327 | |
| 10/25/2024 | 12.17 | 12.38 | 11.89 | 12.10 | 448,854 | |
| 10/24/2024 | 12.13 | 12.42 | 11.92 | 12.10 | 401,473 | |
| 10/23/2024 | 12.45 | 12.59 | 12.00 | 12.13 | 421,148 | |
| 10/22/2024 | 12.45 | 12.52 | 12.28 | 12.47 | 388,973 | |
| 10/21/2024 | 12.79 | 12.82 | 12.42 | 12.52 | 543,426 | |
| 10/18/2024 | 12.88 | 13.00 | 12.43 | 12.73 | 540,554 | |
| 10/17/2024 | 12.79 | 13.12 | 12.22 | 12.84 | 712,882 | |
| 10/16/2024 | 12.44 | 13.54 | 12.15 | 12.60 | 2,028,015 | |
| 10/15/2024 | 12.21 | 12.31 | 11.84 | 12.26 | 763,655 | |
| 10/14/2024 | 12.94 | 13.64 | 12.18 | 12.26 | 982,954 | |
| 10/11/2024 | 11.82 | 12.63 | 11.58 | 12.60 | 735,907 | |
| 10/10/2024 | 11.71 | 12.15 | 11.40 | 11.91 | 1,275,289 | |
| 10/09/2024 | 13.00 | 13.00 | 11.30 | 11.89 | 2,385,377 | |
| 10/08/2024 | 12.46 | 13.25 | 12.33 | 13.11 | 810,307 | |
| 10/07/2024 | 12.71 | 12.74 | 12.22 | 12.42 | 634,104 | |
| 10/04/2024 | 12.49 | 12.89 | 12.43 | 12.70 | 254,463 | |
| 10/03/2024 | 12.49 | 12.61 | 12.27 | 12.38 | 203,125 | |
| 10/02/2024 | 12.41 | 12.80 | 12.30 | 12.58 | 205,379 | |
| 10/01/2024 | 12.63 | 12.79 | 12.22 | 12.48 | 922,513 | |
| 09/30/2024 | 12.94 | 13.08 | 12.60 | 12.70 | 331,163 | |
| 09/27/2024 | 12.92 | 13.08 | 12.61 | 12.90 | 377,016 | |
| 09/26/2024 | 13.14 | 13.31 | 12.70 | 12.75 | 399,753 | |
| 09/25/2024 | 13.02 | 13.15 | 12.71 | 12.86 | 349,141 | |
| 09/24/2024 | 13.10 | 13.27 | 12.77 | 13.06 | 346,459 | |
| 09/23/2024 | 13.55 | 13.66 | 12.82 | 12.97 | 355,829 | |
| 09/20/2024 | 13.85 | 14.00 | 13.34 | 13.54 | 1,224,431 | |
| 09/19/2024 | 13.27 | 14.57 | 13.24 | 13.85 | 986,316 | |
| 09/18/2024 | 13.00 | 13.41 | 12.75 | 13.10 | 1,201,906 | |
| 09/17/2024 | 13.24 | 13.41 | 12.81 | 12.84 | 610,681 | |
| 09/16/2024 | 13.25 | 13.96 | 13.12 | 13.20 | 480,739 | |
| 09/13/2024 | 13.02 | 13.64 | 13.00 | 13.12 | 505,245 | |
| 09/12/2024 | 13.85 | 13.90 | 12.83 | 13.05 | 967,134 | |
| 09/11/2024 | 13.38 | 13.82 | 13.34 | 13.81 | 222,498 | |
| 09/10/2024 | 13.43 | 13.51 | 13.00 | 13.42 | 214,736 | |
| 09/09/2024 | 13.08 | 13.68 | 13.08 | 13.35 | 281,168 | |
| 09/06/2024 | 13.62 | 13.76 | 13.14 | 13.23 | 562,465 | |
| 09/05/2024 | 13.43 | 13.99 | 13.43 | 13.73 | 405,713 | |
| 09/04/2024 | 13.40 | 14.13 | 13.40 | 13.97 | 242,748 | |
| 09/03/2024 | 13.83 | 14.27 | 13.43 | 13.56 | 355,960 | |
| 08/30/2024 | 14.12 | 14.38 | 13.69 | 13.91 | 924,827 |
About UroGen Pharma Stock history
UroGen Pharma investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for UroGen is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in UroGen Pharma will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing UroGen Pharma stock prices may prove useful in developing a viable investing in UroGen Pharma
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 28.8 M | 17 M | |
| Net Loss | -98.8 M | -93.9 M |
UroGen Pharma Quarterly Net Working Capital |
|
UroGen Pharma Stock Technical Analysis
UroGen Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run CEOs Directory Now
CEOs DirectoryScreen CEOs from public companies around the world |
| All Next | Launch Module |
UroGen Pharma Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for UroGen Pharma's price direction in advance. Along with the technical and fundamental analysis of UroGen Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of UroGen to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.41) | |||
| Total Risk Alpha | (0.71) | |||
| Treynor Ratio | (0.21) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share 2.389 | Quarterly Revenue Growth 0.209 | Return On Assets (0.21) | Return On Equity (14.81) |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.